In this context, a selective FXR agonist (BAR704) can obstruct TGF-β promoter binding to p-SMAD3 through SHP-mediated transcription, consequently impeding HSC transdifferentiation and attenuating liver fibrosis [184]. This evidence concerns the gene NR1H4 and Hepatic fibrosis.